Sweden · Delayed Price · Currency is SEK Vimian Group AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 8% revenue growth and double-digit expansion in three of four segments, driven by strong organic performance and strategic acquisitions. Margin pressure from investments is expected to normalize as revenue ramps up, with continued focus on M&A and new market entries.
Fiscal Year 2025
-
Delivered 13% revenue and 11% adjusted EBITDA growth for 2025, with strong Q4 results and margin expansion. Specialty Pharma, MedTech Dental, and Veterinary Services led growth, while U.S. MedTech Orthopedics remains in transition. Robust cash flow and active M&A pipeline support a positive 2026 outlook.
-
Q3 saw 19% revenue growth and 17% adjusted EBITDA growth, with strong results in Specialty Pharma and Veterinary Services, and MedTech returning to organic growth. M&A remains a key strategy, and a $40.2 million court award boosted financials.
-
Q2 saw 15% revenue growth and solid performance in three of four segments, but MedTech orthopedics underperformed due to U.S. market softness. Leadership changes and a key dental acquisition were announced, with a focus on returning MedTech to growth and achieving long-term financial targets.
-
Q1 2025 saw 18% revenue and adjusted EBITDA growth, with strong performance in Specialty Pharma, Veterinary Services, and Diagnostics, while MedTech faced U.S. headwinds. Tariffs are expected to have a limited impact, and high single-digit organic growth is targeted for the year.
Fiscal Year 2024
-
Record Q4 revenue and strong organic growth were driven by Specialty Pharma and the iM3 acquisition. Cash flow and profitability improved, with all segments contributing, despite US MedTech softness and ongoing legal costs. 2025 outlook remains positive, with continued growth and margin normalization expected.
-
Focused on niche animal health markets, the company targets double-digit organic growth and €300 million Adjusted EBITDA by 2030 through innovation, education, and strategic acquisitions. Recent moves include the iM3 dental acquisition and ongoing operational improvements.
-
Double-digit organic growth and margin expansion were achieved in Q3, with strong performance in Specialty Pharma, MedTech, and Veterinary Services. The iM3 acquisition expands the MedTech dental niche, while U.S. MedTech elective surgeries remain soft. Net profit was impacted by one-time costs and FX.
-
Strong Q2 with 11% organic growth, margin expansion, and 57% net profit increase. Specialty Pharma, MedTech, and Veterinary Services all delivered double-digit growth, while leverage dropped to 1.4x after a capital raise. U.S. MedTech softness offset by global strength.